Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
6.47
+0.16 (2.46%)
Aug 25, 2026, 10:45 AM EDT - Market open
Aclaris Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 8.22 | 7.83 | 18.72 | 31.25 | 29.5 | 6.64 |
Other Revenue | - | - | - | - | 0.26 | 0.12 |
| 8.22 | 7.83 | 18.72 | 31.25 | 29.75 | 6.76 | |
Revenue Growth | -51.04% | -58.19% | -40.09% | 5.03% | 340.05% | 4.30% |
Cost of Revenue | 70.49 | 59.93 | 49.04 | 114.25 | 89.77 | 48.53 |
Gross Profit | -62.28 | -52.1 | -30.32 | -83 | -60.02 | -41.77 |
Selling, General & Admin | 23.24 | 21.97 | 22.2 | 31.51 | 25.13 | 23.62 |
Operating Expenses | 23.24 | 21.97 | 22.2 | 31.51 | 25.13 | 23.62 |
Operating Income | -85.51 | -74.08 | -52.53 | -114.51 | -85.15 | -65.38 |
Interest & Investment Income | 6.73 | 7.64 | 7.95 | 8.51 | - | - |
Other Non Operating Income (Expenses) | 3.85 | 3.82 | 1.91 | - | 2.95 | -1.14 |
EBT Excluding Unusual Items | -74.94 | -62.62 | -42.66 | -106 | -82.21 | -66.53 |
Merger & Restructuring Charges | - | - | - | -3.12 | - | - |
Other Unusual Items | -0.8 | -2.3 | -2.5 | 26.9 | -4.7 | -24.34 |
Pretax Income | -75.74 | -64.92 | -132.07 | -88.85 | -86.91 | -90.87 |
Income Tax Expense | - | - | - | -0.37 | - | - |
Earnings From Continuing Operations | -75.74 | -64.92 | -132.07 | -88.48 | -86.91 | -90.87 |
Net Income | -75.74 | -64.92 | -132.07 | -88.48 | -86.91 | -90.87 |
Net Income to Common | -75.74 | -64.92 | -132.07 | -88.48 | -86.91 | -90.87 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 129 | 123 | 77 | 70 | 65 | 57 |
Shares Outstanding (Diluted) | 129 | 123 | 77 | 70 | 65 | 57 |
Shares Change | 25.53% | 58.56% | 10.73% | 7.05% | 14.95% | 33.36% |
EPS (Basic) | -0.59 | -0.53 | -1.71 | -1.27 | -1.33 | -1.60 |
EPS (Diluted) | -0.59 | -0.53 | -1.71 | -1.27 | -1.33 | -1.60 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -62.18 | -47.22 | -20.2 | -79.63 | -68.17 | -52.44 |
Free Cash Flow Per Share | -0.48 | -0.39 | -0.26 | -1.14 | -1.04 | -0.92 |
Gross Margin | - | - | -161.99% | -265.60% | -201.74% | - |
Operating Margin | -1040.43% | -946.52% | -280.59% | -366.44% | -286.21% | -967.08% |
Profit Margin | -921.50% | -829.58% | -705.48% | -283.15% | -292.11% | -1343.96% |
Free Cash Flow Margin | -756.50% | -603.42% | -107.89% | -254.84% | -229.13% | -775.65% |
EBITDA | -85.53 | -74.04 | -52.22 | -114.45 | - | -65.06 |
EBITDA Margin | - | - | -278.95% | - | - | - |
D&A For EBITDA | -0.01 | 0.04 | 0.31 | 0.06 | - | 0.32 |
EBIT | -85.51 | -74.08 | -52.53 | -114.51 | -85.15 | -65.38 |
EBIT Margin | - | - | -280.59% | - | -286.21% | - |
Revenue as Reported | 8.22 | 7.83 | 18.72 | 31.25 | 29.75 | 6.76 |